SHSE:600062'
s Pretax Margin % Range Over the Past 10 Years
Min: 12.31 Med: 15.66 Max: 17.37
Current: 17.3
SHSE:600062's Pretax Margin % is ranked better than 75.52% of 956
companies
in the Drug Manufacturers industry
Industry Median: 7.285
vs SHSE:600062: 17.30
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
China Resources Double-Crane Pharmaceutical Co Pretax Margin % Related Terms
China Resources Double-Crane Pharmaceutical Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co Pretax Margin % Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
SHSE:600062 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co Pretax Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Pretax Margin % of 21.41% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is 37% above median its historical median of 15.66. Over the past decade, China Resources Double-Crane Pharmaceutical Co's Pretax Margin % has ranged from 12.31 to 17.37. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #234 out of 956 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is China Resources Double-Crane Pharmaceutical Co's Pretax Margin % too high?
China Resources Double-Crane Pharmaceutical Co's current Pretax Margin % of 21.41% is 37% above median its 10-year median of 15.66. Over the past 10 years, this metric has ranged from a low of 12.31 to a high of 17.37. The Drug Manufacturers industry median Pretax Margin % is 7.29. China Resources Double-Crane Pharmaceutical Co's value of 21.41% is 193.9% above this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #234 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #234 out of 956 companies for Pretax Margin %. This places China Resources Double-Crane Pharmaceutical Co in the top 25% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.29. China Resources Double-Crane Pharmaceutical Co's value of 21.41% is 193.9% above this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own Pretax Margin % has ranged from 12.31 to 17.37 over the past decade. While the company's 10-year median is 15.66 vs. the industry median of 7.29, China Resources Double-Crane Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current Pretax Margin % of 21.41% is 193.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current Pretax Margin % is 21.41%, which is 37% above median its own 10-year median of 15.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.75, compared to a current price of ¥16.43 — trading 12.4% below its estimated fair value. The current Pretax Margin % is 21.41%, which is 37% above median its 10-year median of 15.66 and 193.9% above the Drug Manufacturers industry median of 7.29. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Pretax Margin % is 21.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥16.43 is trading 12.4% below its estimated GF Value™ of ¥18.75.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
Pretax Margin %: 21.41% (37% above median its 10-year median of 15.66)
GF Value™: ¥18.75 vs. price of ¥16.43 (12.4% below fair value)
Industry Position: 193.9% above the Drug Manufacturers median (#234 of 956)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Business Description
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score
Get the complete analysis for SHSE:600062
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
